Document 0111
 DOCN  M95B0111
 TI    Lack of association between acyclovir use and survival in patients with
       advanced human immunodeficiency virus disease treated with zidovudine.
       Zidovudine Epidemiology Study Group.
 DT    9511
 AU    Gallant JE; Moore RD; Keruly J; Richman DD; Chaisson RE; Department of
       Medicine, Johns Hopkins University School of; Medicine, Baltimore,
       Maryland 21287-6220, USA.
 SO    J Infect Dis. 1995 Aug;172(2):346-52. Unique Identifier : AIDSLINE
       MED/95348530
 AB    To evaluate the association between acyclovir use and survival in
       patients with advanced human immunodeficiency virus infection,
       observational data from 1044 persons with AIDS or AIDS-related complex
       (ARC) and < or = 250 CD4 cells/mm3 following initiation of zidovudine
       were analyzed. Of these patients, 336 (32%) received regular acyclovir
       (> or = 6 weeks in 2 months). There were no differences in mortality
       data between acyclovir users and nonusers overall or when analyzed from
       1 year after first use of zidovudine, from time of AIDS in those with
       ARC at enrollment, from patients with AIDS or < 100 CD4 cells/mm3 at
       enrollment, or from patients taking acyclovir for up to 10 months.
       Acyclovir use was associated with increased mortality (relative hazard,
       1.28; P = .057) independent of herpesvirus infections and of other
       characteristics associated with mortality. In this study, the use of
       acyclovir at doses for treatment of herpes simplex virus infection in
       combination with zidovudine was not associated with prolonged survival.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY/MORTALITY
       Acyclovir/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE  AIDS-Related
       Complex/DRUG THERAPY/MORTALITY  Dose-Response Relationship, Drug  Drug
       Therapy, Combination  Female  Human  HIV Infections/*DRUG
       THERAPY/MORTALITY  Male  Prospective Studies  Support, Non-U.S. Gov't
       Survival Rate  Zidovudine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE
       CLINICAL TRIAL  JOURNAL ARTICLE  MULTICENTER STUDY

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).